zeatin


Also found in: Medical, Wikipedia.

ze·a·tin

 (zē′ə-tĭn)
n.
A cytokinin, C10H13N5O, that is an adenine derivative and was originally isolated from young corn kernels.

[New Latin Zēa, genus name of corn; see zein + -in.]

zeatin

(ˈzɪətɪn)
n
(Botany) botany a plant growth hormone derived from corn and other plants

ze•a•tin

(ˈzi ə tɪn)

n.
a cytokinin occurring in corn, spinach, and peas.
[1963; < New Latin Zea the maize genus (see zein) + (kine)tin]
Translations
zeatina
References in periodicals archive ?
All samples were divided into two parts; one was dried in an oven at 70[degrees]C for 72 h, then weighed for dry matter accumulation, and another was frozen in liquid N2 for one min and kept in a freezer at -70[degrees]C for zeatin (Z), zeatin riboside (ZR), and IAA (indolyl-3-acetic acid) analysis.
Revenues for the first quarter of 2007 included US$24,750,000 recognized in conjunction with the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc.
Under the agreement, Senetek has granted Valeant a paid up license for Kinetin and Zeatin and has assigned to Valeant future royalties from other Kinetin licensees, in return for Senetek receiving a cash payment of $21 million, forgiveness of a $6 million prepaid royalty credit reimbursement obligation that Senetek otherwise would have owed to Valeant, and a right to share in future royalties due to Valeant from other Kinetin licensees through 2011.
Endogenous level of abscisic acid, indole-3-acetic acid, zeatin and zeatin-riboside during the course of adventitious root formation in cuttings of Craigella and Craigella lateral suppressor tomatoes.
Revenues for the first quarter of 2007 included $24,750,000 recognized in conjunction with the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc.
The increase in 2007 revenues, net income and cash flow compared to 2006 is primarily attributable to the effect of the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc.
A variety of natural cell-division factors, now called cytokinins, as N-substituted adenine-conta ining compounds in plants were finally identified in the 1960s; zeatin was the first (Zambryski, 1992).
In addition, the Company has entered into an exclusive global license with Valeant for Senetek's proprietary anti-aging skincare compound, Zeatin, has entered into exclusive licenses for Europe and North America, respectively, for its patented combination drug treatment for erectile dysfunction, Invicorp[R], has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject[R].
8 million in revenues in 2008 and granted Valeant Pharmaceuticals a paid up license for Senetek's first generation patented skin care active ingredient Kinetin and its analog Zeatin in return for $21 million cash and forgiveness of $6 million prepaid royalty credit, and is negotiating third party license agreements for new patent-pending second generation dermatological active ingredients and is completing development of a number of additional compounds.
Kinerase Pro+Therapy contains Zeatin, a Kinerase-exclusive patented technology, proven in studies to improve the appearance of skin roughness, fine lines, wrinkles, mottled hyperpigmentation and other visible signs of skin aging.
Net income for the nine months ended September 30, 2007 included the effect of the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc.
The follow-up skincare technology, Zeatin, is ready for Phase I clinical trials.